A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (NCT04931342)

🧪 Interventions in This Study

• Ipatasertib (DRUG)
• Cobimetinib (DRUG)
• Trastuzumab Emtansine (DRUG)
• Atezolizumab (DRUG)
• Bevacizumab (DRUG)
• Paclitaxel (DRUG)
• Giredestrant (DRUG)
• Abemaciclib (DRUG)
• Inavolisib (DRUG)
• Palbociclib (DRUG)
• Letrozole (DRUG)
• Olaparib (DRUG)
• Luteinizing Hormone-Releasing Hormone (LHRH) Agonists (DRUG)
• Cyclophosphamide (DRUG)
• Inavolisib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (41 Sites)

Showing the first 25 of 41 sites.

• UCSF Helen Diller Family CCC — San Francisco, California
• Washington University School of Medicine — St Louis, Missouri
• Levine Cancer Institute — Charlotte, North Carolina
• Ohio State University — Columbus, Ohio
• University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
• Texas Oncology - Gulf Coast — The Woodlands, Texas
• Virginia Oncology Associates — Norfolk, Virginia
• University of Washington - Seattle Cancer Care Alliance — Seattle, Washington
• Cabrini Hospital — Malvern, Victoria
• Princess Margaret Cancer Center — Toronto, Ontario
• McGill University Health Centre - Glen Site — Montreal, Quebec
• Gynekologicko-porodnicka klinika — Prague,
• CHU Besançon - Hôpital Jean Minjoz — Besançon,
• Centre Francois Baclesse — Caen,
• Centre Leon Berard — Lyon,
• Groupe Hospitalier Diaconesses — Paris,
• Centre Eugène Marquis — Rennes,
• ICO - Site René Gauducheau — Saint-Herblain,
• Institut Claudius Regaud — Toulouse,
• Gustave Roussy — Villejuif,
• Kliniken Essen-Mitte Evang. Huyssens-Stiftung, Klinik für Gynäkologie und gynäkologische Onkologie — Essen,
• Universitätsklinikum Mannheim — Mannheim,
• A.O. U. Consorziale Policlinico di Bari — Bari, Apulia
• Istituto Tumori Napoli — Naples, Campania
• Policlinico Universitario Agostino Gemelli — Rome, Lazio

📞 Contact the Study Coordinator

Phone: (877) 827-3222

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Ovarian Cancer

• Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy — New York, New York
• Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer — Pittsburgh, Pennsylvania
• Trial on Radical Upfront Surgery in Advanced Ovarian Cancer — New York, New York
• Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) — Duarte, California
• Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) — Little Rock, Arkansas
• NeoVax With Nivolumab in Patients With Ovarian Cancer — Boston, Massachusetts

Explore by condition: All Ovarian Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.